Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg

Showing results (101-110 of 333) with videos related to

Pageof 34
Sort By:
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|July 10, 2020
Clinical Frailty Scale for risk stratification in patients with SARS-CoV-2 infectionChristian Labenz, Wolfgang M Kremer, Jörn M Schattenberg, et al.
Oncotarget|September 17, 2017
Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activationNadine Gehrke, Marcus A Wörns, Amrit Mann, et al.
Scientific Reports|June 6, 2023
Metabolic dysfunction-associated fatty liver disease in people living with HIVMaurice Michel, Christian Labenz, Angelo Armandi, et al.
Journal of Lipid Research|November 13, 2016
Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based studyMarcin Krawczyk, Monika Rau, Jörn M Schattenberg, et al.
Hepatology Communications|December 2, 2024
Blocking interleukin-1 receptor type 1 (IL-1R1) signaling in hepatocytes slows down diethylnitrosamine-induced liver tumor growth in obese miceNadine Gehrke, Lea J Hofmann, Beate K Straub, et al.
Plos One|June 16, 2022
Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-RegistryMonika Rau, Peter Buggisch, Stefan Mauss, et al.
Journal of Hepatology|January 26, 2018
Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammationNadine Gehrke, Nadine Hövelmeyer, Ari Waisman, et al.
JHEP Reports : Innovation in Hepatology|September 22, 2025
Proteomic signatures reflect effects of semaglutide treatment for MASHJörn M Schattenberg, Henning Grønbæk, Iris Kliers, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 3, 2023
Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patientsMartin Franck, Katharina John, Sherin Al Aoua, et al.
Digestive Diseases (Basel, Switzerland)|July 5, 2017
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with SorafenibChristian Labenz, Vera Prenosil, Sandra Koch, et al.
Pageof 34

Showing results (101-110 of 333) with videos related to

Sort By:
Pageof 34
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|July 10, 2020
Clinical Frailty Scale for risk stratification in patients with SARS-CoV-2 infectionChristian Labenz, Wolfgang M Kremer, Jörn M Schattenberg, et al.
Oncotarget|September 17, 2017
Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activationNadine Gehrke, Marcus A Wörns, Amrit Mann, et al.
Scientific Reports|June 6, 2023
Metabolic dysfunction-associated fatty liver disease in people living with HIVMaurice Michel, Christian Labenz, Angelo Armandi, et al.
Journal of Lipid Research|November 13, 2016
Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based studyMarcin Krawczyk, Monika Rau, Jörn M Schattenberg, et al.
Hepatology Communications|December 2, 2024
Blocking interleukin-1 receptor type 1 (IL-1R1) signaling in hepatocytes slows down diethylnitrosamine-induced liver tumor growth in obese miceNadine Gehrke, Lea J Hofmann, Beate K Straub, et al.
Plos One|June 16, 2022
Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-RegistryMonika Rau, Peter Buggisch, Stefan Mauss, et al.
Journal of Hepatology|January 26, 2018
Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammationNadine Gehrke, Nadine Hövelmeyer, Ari Waisman, et al.
JHEP Reports : Innovation in Hepatology|September 22, 2025
Proteomic signatures reflect effects of semaglutide treatment for MASHJörn M Schattenberg, Henning Grønbæk, Iris Kliers, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|August 3, 2023
Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patientsMartin Franck, Katharina John, Sherin Al Aoua, et al.
Digestive Diseases (Basel, Switzerland)|July 5, 2017
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with SorafenibChristian Labenz, Vera Prenosil, Sandra Koch, et al.
Pageof 34